Home > Resources > Whitepapers > Sample Preparation Technologies for Improved Peptide Quantitation Workflow.

Sample Preparation Technologies for Improved Peptide Quantitation Workflow.

New sample preparation technologies can bring considerable benefit in terms of higher sample throughput and data quality to peptide quantitation. When these are combined with advances across the entire workflow, better quality, analysis speed, and greater return on investment are all achievable

Spotlight

Biotech & Pharma Professionals Network

We are a world wide community joining 90,000 members in Biotech, Health Care, Medical, Pharma, Clinical and the Life Sciences. We welcome folk in diagnostics, the medical device field, clinical trials, research, QA / QC, academics, writers, job hunters, students, and recruiters. We have an active Forum with a lively discussion and jobs kept apart.

OTHER WHITEPAPERS

Challenges and Solutions for Gene Therapy manufacturing

whitePaper | November 17, 2022

Gene therapy is the modification of specific genes in targeted cells in order to address genetic mutations that cause some of the most debilitating human conditions.

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

Using Clinical Breakpoints to Improve Antimicrobial Resistance Detection

whitePaper | December 13, 2022

Define the ongoing pandemic of antimicrobial resistance. Discuss how we can address the ongoing pandemicin the Clinical Microbiology Laboratory

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.